This Library Guide is a collection of useful documents & evidence on the efficacy, effectiveness and impact of MPox vaccines to support NITAG members and other policy makers throughout Africa with making evidence-based recommendations.
Fenner, F., Henderson, D. A., Arita, I., Ježek, Z., & Ladnyi, I. D. (1987). Smallpox and its eradication. Geneva: WHO, 210.bullwho00076-0026.pdf (nih.gov)
3, Monkeypox: experts give virus variants new names (News release, 12 August 2022). Geneva: World Health Organization (https://www.who.int/news/item/12-08-2022- monkeypox--experts-give-virus-variants-new-names)
Breman, J. G., Steniowski, M. V., Zanotto, E., Gromyko, A. I., & Arita, I. (1980). Human monkeypox, 1970-79. Bulletin of the World Health Organization, 58(2), 165. Human monkeypox, 1970-79 - PMC (nih.gov)
Guarner, J., Johnson, B. J., Paddock, C. D., Shieh, W. J., Goldsmith, C. S., Reynolds, M. G., ... & Veterinary Monkeypox Virus Working Group. (2004). Monkeypox transmission and pathogenesis in prairie dogs. Emerging infectious diseases, 10(3), 426. doi: 10.3201/eid1003.030878
Laurenson-Schafer H et al. Description of the first global outbreak of mpox: an analysis of global surveillance data. Lancet Glob Health. 2023;11:e1012–23. DOI: 10.1016/S2214-109X(23)00198-5
Americo, J. L., Earl, P. L., & Moss, B. (2023). Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb. 1 in a small animal model. Proceedings of the National Academy of Sciences, 120(8), e2220415120. https://doi.org/10.1073/pnas.2220415120
World Health Organization. (2023). Multi-Country Outbreak of Mpox, External Situation Report 31.Multi-country outbreak of mpox, External situation report#31 – 22 December 2023 (who.int)
Operational framework for the deployment of the WHO smallpox vaccine emergency stockpile in response to a smallpox event. Geneva: World Health Organization; 2017 (https://www.who.int/publications/i/item/WHO-WHE-IHM-2017-14)
Leggiadro, R. J. (2011). Major Increase in Human Monkeypox Incidence 30 Years After Smallpox Vaccination Campaigns Cease in the Democratic Republic of Congo: AW Rimoin et al.: PNAS.: Published online before print August 30, 2010. The Pediatric Infectious Disease Journal, 30(1), 2. (NOt OA)
Clay, P. A., Asher, J. M., Carnes, N., Copen, C. E., Delaney, K. P., Payne, D. C., ... & Spicknall, I. H. (2024). Modelling the impact of vaccination and sexual behaviour adaptations on mpox cases in the USA during the 2022 outbreak. Sexually Transmitted Infections, 100(2), 70-76.doi: 10.1136/sextrans-2023-055922
Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance. Geneva: World Health Organization; 2022 (https://www. who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1)
Petersen, E., Kantele, A., Koopmans, M., Asogun, D., Yinka-Ogunleye, A., Ihekweazu, C., & Zumla, A. (2019). Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infectious Disease Clinics, 33(4), 1027-1043. https://www.id.theclinics.com/article/S0891-5520(19)30017-0/pdf
Ogoina D et al. The 2017 human monkeypox outbreak in Nigeria – Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS One.
Yinka-Ogunleye, A., Dalhat, M., Akinpelu, A., Aruna, O., Garba, F., Ahmad, A., ... & Abubakar, I. (2023). Mpox (monkeypox) risk and mortality associated with HIV infection: a national case–control study in Nigeria. BMJ Global Health, 8(11), e013126.https://gh.bmj.com/content/bmjgh/8/11/e013126.full.pdf
Mitjà, O., Alemany, A., Marks, M., Mora, J. I. L., Rodríguez-Aldama, J. C., Silva, M. S. T., ... & Paredes, M. T. (2023). Mpox in people with advanced HIV infection: a global case series. The Lancet, 401(10380), 939-949.
Berry, M. T., Khan, S. R., Schlub, T. E., Notaras, A., Kunasekaran, M., Grulich, A. E., ... & Khoury, D. S. (2024). Predicting vaccine effectiveness for mpox. Nature Communications, 15(1), 3856.https://www.nature.com/articles/s41467-024-48180-w.pdf
Hazra, A., Zucker, J., Bell, E., Flores, J., Gordon, L., Mitjà, O., ... & Marchetta, L. (2024). Mpox in people with past infection or a complete vaccination course: a global case series. The Lancet Infectious Diseases, 24(1), 57-64.https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(23)00492-9.pdf
Heiner, G. G., Fatima, N., & McCrumb Jr, F. R. (1971). A study of intrafamilial transmission of smallpox. American Journal of Epidemiology, 94(4), 316-326.https://iris.who.int/bitstream/handle/10665/67491/WHO_SE_71.33.pdf?sequence=1
Henderson, D. A., Inglesby Jr, T. V., O'Toole, T., & Mortimer, P. P. (2003). Can postexposure vaccination against smallpox succeed?. Clinical infectious diseases, 36(5), 622-629.https://watermark.silverchair.com/36-5-622.pdf
Hatch, G. J., Graham, V. A., Bewley, K. R., Tree, J. A., Dennis, M., Taylor, I., ... & Vipond, J. (2013). Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. Journal of virology, 87(14), 7805-7815.https://journals.asm.org/doi/pdf/10.1128/jvi.03481-12
Pischel, L., Martini, B. A., Yu, N., Cacesse, D., Tracy, M., Kharbanda, K., ... & Omer, S. B. (2024). Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine.https://doi.org/10.1016/j.vaccine.2024.06.021
Bertran, M., Andrews, N., Davison, C., Dugbazah, B., Boateng, J., Lunt, R., ... & Bernal, J. L. (2023). Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. The Lancet Infectious Diseases, 23(7), 828-835.https://doi.org/10.1016/S1473-3099(23)00057-9
Fontán-Vela, M., Hernando, V., Olmedo, C., Coma, E., Martínez, M., Moreno-Perez, D., ... & Monge, S. (2024). Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a population at high risk of mpox: a Spanish cohort study. Clinical Infectious Diseases, 78(2), 476-483.https://doi.org/10.1093/cid/ciad645
Hens, M., Brosius, I., Berens-Riha, N., Coppens, J., Van Gestel, L., Rutgers, J., ... & Ariën, K. (2023). Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak. New microbes and new infections, 52, 101093.https://doi.org/10.1016/j.nmni.2023.101093
Dalton, A. F. (2023). Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study—United States, August 19, 2022–March 31, 2023. MMWR. Morbidity and mortality weekly report, 72.https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a3.htm?trk=public_post_comment-text
Rosenberg, E. S. (2023). Effectiveness of JYNNEOS vaccine against diagnosed mpox infection—New York, 2022. MMWR. Morbidity and Mortality Weekly Report, 72.https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a4.htm
Payne, A. B. (2022). Reduced risk for mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons—43 US jurisdictions, July 31–October 1, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.https://www.cdc.gov/mmwr/volumes/71/wr/mm7149a5.htm?ftag=YHF4eb9d17
Payne, A.B., (2022). Incidence of monkeypox among unvaccinated persons compared with persons receiving≥ 1 JYNNEOS vaccine dose—32 US jurisdictions, July 31–September 3, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.https://www.cdc.gov/mmwr/volumes/71/wr/mm7140e3.htm
Wolff Sagy Y et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023;29:748–52. d (NOT OA)
Ramchandani, M. S., Berzkalns, A., Cannon, C. A., Dombrowski, J. C., Brown, E., Chow, E. J., ... & Golden, M. R. (2023, November). Effectiveness of the modified vaccinia Ankara vaccine against mpox in men who have sex with men: a retrospective cohort analysis, Seattle, Washington. In Open Forum Infectious Diseases (Vol. 10, No. 11, p. ofad528). US: Oxford University Press.https://doi.org/10.1093/ofid/ofad528
Brousseau, N., Carazo, S., Febriani, Y., Padet, L., Hegg-Deloye, S., Cadieux, G., ... & Skowronski, D. M. (2024). Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk. Clinical Infectious Diseases, 78(2), 461-469.https://doi.org/10.1093/cid/ciad584
Impact of vaccination on mpox incidence in MSM on prep in the ANRS 174 doxyvac trial.2023. (www.croiconference.org/abstract/impact-of-vaccination-on-mpox-incidence-in-msm-on-prep-in-the-anrs-174-doxyvac-trial
Deputy, N. P., Deckert, J., Chard, A. N., Sandberg, N., Moulia, D. L., Barkley, E., ... & Feldstein, L. R. (2023). Vaccine effectiveness of JYNNEOS against mpox disease in the United States. New England Journal of Medicine, 388(26), 2434-2443. (NOT OA)
Agustí C et al. Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain. Nat Commun. 2023;
Dalton, A. F. (2023). Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study—United States, August 19, 2022–March 31, 2023. MMWR. Morbidity and mortality weekly report, 72. https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a3.htm?trk=public_post_comment-text
Nishiyama, Y., Fujii, T., Kanatani, Y., Shinmura, Y., Yokote, H., & Hashizume, S. (2015). Freeze-dried live attenuated smallpox vaccine prepared in cell culture “LC16-KAKETSUKEN”: post-marketing surveillance study on safety and efficacy compliant with good clinical practice. Vaccine, 33(45), 6120-6127. https://doi.org/10.1016/j.vaccine.2015.09.067
Saito, T., Fujii, T., Kanatani, Y., Saijo, M., Morikawa, S., Yokote, H., ... & Kuwabara, N. (2009). Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. Jama, 301(10), 1025-1033. (NOT OA)
Kennedy, J. S., Gurwith, M., Dekker, C. L., Frey, S. E., Edwards, K. M., Kenner, J., ... & Greenberg, R. N. (2011). Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. Journal of Infectious Diseases, 204(9), 1395-1402. https://doi.org/10.1093/infdis/jir527
Morino, E., Mine, S., Tomita, N., Uemura, Y., Shimizu, Y., Saito, S., ... & Ujiie, M. (2024). Mpox neutralizing antibody response to LC16m8 vaccine in healthy adults. NEJM evidence, 3(3), EVIDoa2300290. (NOT OA)
Artenstein, A. W., Johnson, C., Marbury, T. C., Morrison, D., Blum, P. S., Kemp, T., ... & Monath, T. P. (2005). A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine, 23(25), 3301-3309. (NOT OA)
Frey, S. E., Newman, F. K., Kennedy, J. S., Ennis, F., Abate, G., Hoft, D. F., & Monath, T. P. (2009). Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults. Vaccine, 27(10), 1637-1644. (NOT OA)
Monath, T. P., & Frey, S. E. (2009). Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine, 27(10), 1645-1650.(NOT OA)
Pittman, P. R., Hahn, M., Lee, H. S., Koca, C., Samy, N., Schmidt, D., ... & Chaplin, P. (2019). Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. New England Journal of Medicine, 381(20), 1897-1908. (NOT OA)
Ilchmann, H., Samy, N., Reichhardt, D., Schmidt, D., Powell, J. D., Meyer, T. P., ... & Chaplin, P. (2023). One-and two-dose vaccinations with modified vaccinia Ankara-Bavarian nordic induce durable B-cell memory responses comparable to replicating smallpox vaccines. The Journal of Infectious Diseases, 227(10), 1203-1213.https://doi.org/10.1093/infdis/jiac455
Priyamvada, L., Carson, W. C., Ortega, E., Navarra, T., Tran, S., Smith, T. G., ... & Townsend, M. B. (2022). Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo. Vaccine, 40(50), 7321-7327. (NOT OA)
Eckart, R. E., Love, S. S., Atwood, J. E., Arness, M. K., Cassimatis, D. C., Campbell, C. L., ... & Department of Defense Smallpox Vaccination Clinical Evaluation Team. (2004). Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. Journal of the American College of Cardiology, 44(1), 201-205. DOI: 10.1016/j.jacc.2004.05.004
Duffy, J. (2022). Safety monitoring of JYNNEOS vaccine during the 2022 mpox outbreak—United States, May 22–October 21, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.https://www.cdc.gov/mmwr/volumes/71/wr/mm7149a4.htm
Kenner, J., Cameron, F., Empig, C., Jobes, D. V., & Gurwith, M. (2006). LC16m8: an attenuated smallpox vaccine. Vaccine, 24(47-48), 7009-7022.https://doi.org/10.1016/j.vaccine.2006.03.087
Karita, E., Nyombayire, J., Ingabire, R., Mazzei, A., Sharkey, T., Mukamuyango, J., ... & Wall, K. M. (2022). Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26. ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial. Trials, 23(1), 513. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06360-3
Overton, E. T., Stapleton, J., Frank, I., Hassler, S., Goepfert, P. A., Barker, D., ... & Chaplin, P. (2015). Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. In Open forum infectious diseases (Vol. 2, No. 2, p. ofv040). US: Oxford University Press.https://doi.org/10.1093/ofid/ofv040
Overton, E. T., Lawrence, S. J., Stapleton, J. T., Weidenthaler, H., Schmidt, D., Koenen, B., ... & Chaplin, P. (2020). A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine, 38(11), 2600-2607. (NOT OA)
Okumura, N., Morino, E., Nomoto, H., Yanagi, M., Takahashi, K., Iwasaki, H., ... & Ujiie, M. (2024). Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial. medRxiv, 2024-06.https://www.medrxiv.org/content/10.1101/2024.06.06.24308551v1.full.pdf
Walsh, S. R., Wilck, M. B., Dominguez, D. J., Zablowsky, E., Bajimaya, S., Gagne, L. S., ... & Baden, L. R. (2013). Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. The Journal of infectious diseases, 207(12), 1888-1897.https://doi.org/10.1093/infdis/jit105
MacIntyre, C. R., Heslop, D. J., Nguyen, P., Adam, D., Trent, M., & Gerber, B. J. (2022). Pacific Eclipse–A tabletop exercise on smallpox pandemic response. Vaccine, 40(17), 2478-2483. https://doi.org/10.1016/j.vaccine.2021.10.081
Costantino, V., Kunasekaran, M., & MacIntyre, C. R. (2021). Modelling of optimal vaccination strategies in response to a bioterrorism associated smallpox outbreak. Human Vaccines & Immunotherapeutics, 17(3), 738-746. https://doi.org/10.1080/21645515.2020.1800324
Mohanty, B., Costantino, V., Narain, J., Chughtai, A. A., Das, A., & MacIntyre, C. R. (2020). Modelling the impact of a smallpox attack in India and influence of disease control measures. BMJ open, 10(12), e038480. https://bmjopen.bmj.com/content/bmjopen/10/12/e038480.full.pdf
MacIntyre, C. R., Costantino, V., & Kunasekaran, M. P. (2019). Health system capacity in Sydney, Australia in the event of a biological attack with smallpox. PLoS One, 14(6), e0217704. https://doi.org/10.1371/journal.pone.0217704
Yinka-Ogunleye, A., Aruna, O., Dalhat, M., Ogoina, D., McCollum, A., Disu, Y., ... & Satheshkumar, P. S. (2019). Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. The Lancet Infectious Diseases, 19(8), 872-879. https://www.thelancet.com/action/showPdf?pii=S1473-3099%2819%2930294-4
Rimoin, A. W., Mulembakani, P. M., Johnston, S. C., Lloyd Smith, J. O., Kisalu, N. K., Kinkela, T. L., ... & Muyembe, J. J. (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences, 107(37), 16262-16267. https://doi.org/10.1073/pnas.1005769107
World Health Organization. (2022). Clinical management and infection prevention and control for monkeypox: interim rapid response guidance, 10 June 2022 (No. WHO/MPX/Clinical_and_IPC/2022.1). World Health Organization. https://iris.who.int/bitstream/handle/10665/355798/WHO-MPX-Clinical_and_IPC-2022.1-eng.pdf?sequence=1
Yinka-Ogunleye, A., Dalhat, M., Akinpelu, A., Aruna, O., Garba, F., Ahmad, A., ... & Abubakar, I. (2023). Mpox (monkeypox) risk and mortality associated with HIV infection: a national case–control study in Nigeria. BMJ Global Health, 8(11), e013126. https://gh.bmj.com/content/bmjgh/8/11/e013126.full.pdf
Petersen, E., Kantele, A., Koopmans, M., Asogun, D., Yinka-Ogunleye, A., Ihekweazu, C., & Zumla, A. (2019). Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infectious Disease Clinics, 33(4), 1027-1043.. https://www.id.theclinics.com/action/showPdf?pii=S0891-5520%2819%2930017-0
Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A et al. The 2017 human monkeypox outbreak in Nigeria-Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214229
Ježek, Z., Grab, B., Szczeniowski, M. V., Paluku, K. M., & Mutombo, M. (1988). Human monkeypox: secondary attack rates. Bulletin of the World Health Organization, 66(4), 465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491159/pdf/bullwho00069-0046.pdf
Meyer, H. (2013). Summary report on first, second and third generation smallpox vaccines. World Health Organization: Geneva, Switzerland.Artenstein, A. W., Johnson, C., Marbury, T. C., Morrison, D., Blum, P. S., Kemp, T., & Monath, T. P. (2005). A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine, 23(25), 3301-3309.
Frey, S. E., Newman, F. K., Kennedy, J. S., Ennis, F., Abate, G., Hoft, D. F., & Monath, T. P. (2009). Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults. Vaccine, 27(10), 1637-1644.
Monath, T. P., & Frey, S. E. (2009). Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine, 27(10), 1645-1650.
Pittman, P. R., Hahn, M., Lee, H. S., Koca, C., Samy, N., Schmidt, D., ... & Chaplin, P. (2019). Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. New England Journal of Medicine, 381(20), 1897-1908.
Hatch, G. J., Graham, V. A., Bewley, K. R., Tree, J. A., Dennis, M., Taylor, I., ... & Vipond, J. (2013). Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. Journal of virology, 87(14), 7805-7815.
Faix, D. J., Gordon, D. M., Perry, L. N., Raymond-Loher, I., Tati, N., Lin, G., ... & Decker, M. D. (2020). Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine, 38(46), 7323-7330.
McNeil, M. M., Cano, M., Miller, E. R., Petersen, B. W., Engler, R. J., & Bryant-Genevier, M. G. (2014). Ischemic cardiac events and other adverse events following ACAM2000® smallpox vaccine in the Vaccine Adverse Event Reporting System. Vaccine, 32(37), 4758-4765.
Decker, M. D., Garman, P. M., Hughes, H., Yacovone, M. A., Collins, L. C., Fegley, C. D., ... & Gordon, D. M. (2021). Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. Vaccine, 39(39), 5541-5547.
Nishiyama, Y., Fujii, T., Kanatani, Y., Shinmura, Y., Yokote, H., & Hashizume, S. (2015). Freeze-dried live attenuated smallpox vaccine prepared in cell culture “LC16-KAKETSUKEN”: post-marketing surveillance study on safety and efficacy compliant with good clinical practice. Vaccine, 33(45), 6120-6127.
Saito, T., Fujii, T., Kanatani, Y., Saijo, M., Morikawa, S., Yokote, H., ... & Kuwabara, N. (2009). Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. Jama, 301(10), 1025-1033.
Kennedy, J. S., Gurwith, M., Dekker, C. L., Frey, S. E., Edwards, K. M., Kenner, J., ... & Greenberg, R. N. (2011). Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. Journal of Infectious Diseases, 204(9), 1395-1402.
M.K. H. Research summary of an attenuated lc16m8 smallpox vaccine by the smallpox vaccine research committee (SVRC). 2005
Zaeck, L. M., Lamers, M. M., Verstrepen, B. E., Bestebroer, T. M., Van Royen, M. E., Götz, H., ... & De Vries, R. D. (2023). Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nature medicine, 29(1), 270-278. https://www.nature.com/articles/s41591-022-02090-w
Arbel, R., Sagy, Y. W., Zucker, R., Arieh, N. G., Markovits, H., Abu-Ahmad, W., ... & Netzer, D. (2022). Effectiveness of a single-dose modified vaccinia Ankara in human monkeypox: an observational study.https://www.researchsquare.com/article/rs-1976861/v2
Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., ... & McShane, H. (2013). Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. The Lancet, 381(9871), 1021-1028.
Afolabi, M. O., Tiono, A. B., Adetifa, U. J., Yaro, J. B., Drammeh, A., Nébié, I., ... & Sirima, S. B. (2016). Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Molecular Therapy, 24(8), 1470-1477. DOI:https://doi.org/10.1038/mt.2016.83
Ota, M. O., Odutola, A. A., Owiafe, P. K., Donkor, S., Owolabi, O. A., Brittain, N. J., ... & McShane, H. (2011). Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Science translational medicine, 3(88), 88ra56-88ra56.
Rao, A. K. (2022). Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR. Morbidity and mortality weekly report, 71.https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.
Overton, E. T., Lawrence, S. J., Stapleton, J. T., Weidenthaler, H., Schmidt, D., Koenen, B., ... & Chaplin, P. (2020). A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine, 38(11), 2600-2607.
Walsh, S. R., Wilck, M. B., Dominguez, D. J., Zablowsky, E., Bajimaya, S., Gagne, L. S., ... & Baden, L. R. (2013). Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. The Journal of infectious diseases, 207(12), 1888-1897.https://doi.org/10.1093/infdis/jit105
Greenberg, R. N., Hurley, Y., Dinh, D. V., Mraz, S., Vera, J. G., von Bredow, D., ... & Chaplin, P. (2015). A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18–40 year old subjects with diagnosed atopic dermatitis. PloS one, 10(10), e0138348. https://doi.org/10.1371/journal.pone.0138348
Von Sonnenburg, F., Perona, P., Darsow, U., Ring, J., von Krempelhuber, A., Vollmar, J., ... & Chaplin, P. (2014). Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine, 32(43), 5696-5702.
Monkeypox multi-country outbreak - first update. 2022
Spicknall, I. H. (2022). Modeling the impact of sexual networks in the transmission of monkeypox virus among gay, bisexual, and other men who have sex with men—United States, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.https://www.cdc.gov/mmwr/volumes/71/wr/mm7135e2.htm.
Thy, M., Peiffer-Smadja, N., Mailhe, M., Kramer, L., Ferré, V. M., Houhou, N., ... & Ghosn, J. (2022). Breakthrough infections after postexposure vaccination against mpox. New England Journal of Medicine, 387(26), 2477-2479.
Keckler, M. S., Reynolds, M. G., Damon, I. K., & Karem, K. L. (2013). The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data. Vaccine, 31(45), 5192-5201.
Frey, S. E., Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., El Sahly, H., ... & Belshe, R. B. (2015). Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine, 33(39), 5225-5234.
